1,8-Naphthyridine derivatives as cholinesterases inhibitors and cell Ca 2+ regulators, a multitarget strategy for Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2807-2823

  Egea, Javier ^a   de los Rios, Cristobal ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

1,8 naphthyridines; Acetylcholinesterase; Alzheimer's disease; Drug discovery; Friedl nder reaction; Voltagedependant calcium channels.

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 1,8 NAPHTHYRIDINE DERIVATIVE; 2 AMINO 3 CYANOHETEROCYCLE DERIVATIVE; 4 PHENYL 1,8 NAPHTHYRIDINE DERIVATIVE; 4H PYRANO[2,3 B]PYRIDINE DERIVATIVE; CALCIUM CHANNEL; CALCIUM ION; CHOLINESTERASE INHIBITOR; CYCLOALKANONE; FUSED CARBON NITROGEN SULFUR HETEROCYCLE; NIFEDIPINE; PROTEIN BCL 2; QUINOLINE DERIVATIVE; TACRINE; THIENO[2,3 B]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL DEATH; CELL ISOLATION; CELL SURVIVAL; CHEMICAL REACTION; CHROMAFFIN CELL; CONCENTRATION (PARAMETERS); DRUG SYNTHESIS; FRIEDLANDER REACTION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; ANIMALS; CALCIUM; CALCIUM CHANNELS; CHOLINESTERASE INHIBITORS; HUMANS; NAPHTHYRIDINES;

EID: 82055186667     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184418     Document Type: Article

References (106)

1. Goedert, M.; Spillantini, M. G. A century of Alzheimer's disease. Science, 2006, 314(5800), 777-781.
2. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des., 2006, 12(33), 4377-4387.
3. Gong, C. X.; Iqbal, K. Hyperphosphorylation of microtubuleassociated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem., 2008, 15(23), 2321-2328.
4. Pratico, D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N Y Acad. Sci., 2008, 1147, 70-78.
5. Cummings, J. L. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev. Neurol. Dis. 2004, 1(2), 60-69.
6. Rafii, M. S.; Aisen, P. S. Recent developments in Alzheimer's disease therapeutics. BMC Med., 2009, 7, 7.
7. van Marum, R. J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol., 2008, 22(3), 265-274.
8. Fillit, H. M.; Doody, R. S.; Binaso, K.; Crooks, G. M.; Ferris, S. H.; Farlow, M. R.; Leifer, B.; Mills, C.; Minkoff, N.; Orland, B.; Reichman, W. E.; Salloway, S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am. J. Geriatr. Pharmacother., 2006, 4 (Suppl A), S9-S24; quiz S25-S28.
9. Racchi, M.; Mazzucchelli, M.; Porrello, E.; Lanni, C.; Govoni, S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol. Res., 2004, 50(4), 441-451.
10. Talesa, V. N. Acetylcholinesterase in Alzheimer's disease. Mech. Ageing Dev., 2001, 122(16), 1961-1969.
11. O'Neill, M. F. Difficult times for Alzheimer's treatments. Drug Discov. Toda,y 2005, 10(20), 1333-1335.
12. Bullock, R.; Touchon, J.; Bergman, H.; Gambina, G.; He, Y.; Rapatz, G.; Nagel, J.; Lane, R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr. Med. Res. Opin., 2005, 21(8), 1317-1327.
13. Li, W.; Mak, M.; Jiang, H.; Wang, Q.; Pang, Y.; Chen, K.; Han, Y. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics, 2009, 6(1), 187-201.
14. Lorrio, S.; Sobrado, M.; Arias, E.; Roda, J. M.; Garcia, A. G.; Lopez, M. G. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther., 2007, 322(2), 591-599.
15. Martorana, A.; Esposito, Z.; Koch, G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther., 16(4), 235-245.
16. Musial, A.; Bajda, M.; Malawska, B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem., 2007, 14(25), 2654-2679.
17. Martinez, A.; Castro, A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs, 2006, 15(1), 1-12.
18. Arias, E.; Ales, E.; Gabilan, N. H.; Cano-Abad, M. F.; Villarroya, M.; Garcia, A. G.; Lopez, M. G. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology, 2004, 46(1), 103-114.
19. Melo, J. B.; Sousa, C.; Garcao, P.; Oliveira, C. R.; Agostinho, P. Galantamine protects against oxidative stress induced by amyloidbeta peptide in cortical neurons. Eur. J. Neurosci., 2009, 29(3), 455-464.
20. Noh, M. Y.; Koh, S. H.; Kim, Y.; Kim, H. Y.; Cho, G. W.; Kim, S. H. Neuroprotective effects of donepezil through inhibition of GSK- 3 activity in amyloid-beta-induced neuronal cell death. J. Neurochem., 2009, 108(5), 1116-1125.
21. Shanks, M.; Kivipelto, M.; Bullock, R.; Lane, R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr. Med. Res. Opin., 2009, 25(10), 2439-2446.
22. Munoz-Torrero, D. Acetylcholinesterase inhibitors as diseasemodifying therapies for Alzheimer's disease. Curr. Med. Chem., 2008, 15(24), 2433-2455.
23. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16(4), 881-891.
24. Castro, A.; Martinez, A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini. Rev. Med. Chem., 2001, 1(3), 267-272.
25. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta- Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol., 2003, 65(3), 407-416.
26. Garcia-Palomero, E.; Munoz, P.; Usan, P.; Garcia, P.; Delgado, E.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martinez, A. Potent beta-amyloid modulators. Neurodegener. Dis., 2008, 5(3- 4), 153-156.
27. Espinoza-Fonseca, L. M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem., 2006, 14(4), 896-897.
28. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372.
29. Alonso, D.; Dorronsoro, I.; Rubio, L.; Munoz, P.; Garcia- Palomero, E.; Del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Castro, A.; Medina, M.; Martinez, A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem., 2005, 13(24), 6588-6597.
30. Camps, P.; Formosa, X.; Galdeano, C.; Gomez, T.; Munoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M. V.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J. Novel donepezilbased inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase- induced beta-amyloid aggregation. J. Med. Chem., 2008, 51(12), 3588-3598.
31. Rodriguez-Franco, M. I.; Fernandez-Bachiller, M. I.; Perez, C.; Hernandez-Ledesma, B.; Bartolome, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem., 2006, 49(2), 459-462.
32. Fernandez-Bachiller, M. I.; Perez, C.; Campillo, N. E.; Paez, J. A.; Gonzalez-Munoz, G. C.; Usan, P.; Garcia-Palomero, E.; Lopez, M. G.; Villarroya, M.; Garcia, A. G.; Martinez, A.; Rodriguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem, 2009, 4(5), 828-841.
33. Fernandez-Bachiller, M. I.; Perez, C.; Gonzalez-Munoz, G. C.; Conde, S.; Lopez, M. G.; Villarroya, M.; Garcia, A. G.; Rodriguez- Franco, M. I. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem., 2010, 53(13), 4927-4937.
34. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-targetdirected coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18(1), 423-426.
35. Camps, P.; Formosa, X.; Galdeano, C.; Munoz-Torrero, D.; Ramirez, L.; Gomez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodriguez- Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2- c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J. Med. Chem., 2009, 52(17), 5365-5379.
36. Weinstock, M.; Kirschbaum-Slager, N.; Lazarovici, P.; Bejar, C.; Youdim, M. B.; Shoham, S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti- Alzheimer drugs. Ann. N Y Acad. Sci., 2001, 939, 148-161.
37. Leon, R.; de Los Rios, C.; Marco-Contelles, J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Synthesis of 6-amino-1,4- dihydropyridines that prevent calcium overload and neuronal death. Eur. J. Med. Chem., 2008, 43(3), 668-674.
38. Bova, S.; Saponara, S.; Rampa, A.; Gobbi, S.; Cima, L.; Fusi, F.; Sgaragli, G.; Cavalli, M.; de los Rios, C.; Striessnig, J.; Bisi, A. Anthracene based compounds as new L-type Ca2+ channel blockers: design, synthesis, and full biological profile. J. Med. Chem., 2009, 52(5), 1259-1262.
39. Leon, R.; de los Rios, C.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Luque, F. J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Med. Chem., 2008, 16(16), 7759-7769.
40. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodriguez- Franco, M. I.; Lopez, B.; Lopez, M. G.; Garcia, A. G.; Carreiras Mdo, C.; Villarroya, M. Tacripyrines, the first tacrinedihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52(9), 2724-2732.
41. Samadi, A.; Marco-Contelles, J.; Soriano, E.; Álvarez-Pérez, M.; Chioua, M.; Romero, A.; González-Lafuente, L.; Gandía, L.; Roda, J. M.; López, M. G.; Villarroya, M.; García, A. G.; Ríos, C. d. l. Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine- 3,5-dicarbonitriles. Bioorg. Med. Chem., 2010, 18(16), 5861-5872.
42. Verkhratsky, A.; Toescu, E. C. Calcium and neuronal ageing. Trends Neurosci., 1998, 21(1), 2-7.
43. Khachaturian, Z. S. Calcium hypothesis of Alzheimer's disease and brain aging. Ann. NY Acad. Sci., 1994, 747, 1-11.
44. Fraser, S. P.; Suh, Y. H.; Djamgoz, M. B. Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Trends Neurosci., 1997, 20(2), 67-72.
45. Kruman, I.; Guo, Q.; Mattson, M. P. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res., 1998, 51(3), 293-308.
46. Dreses-Werringloer, U.; Lambert, J. C.; Vingtdeux, V.; Zhao, H.; Vais, H.; Siebert, A.; Jain, A.; Koppel, J.; Rovelet-Lecrux, A.; Hannequin, D.; Pasquier, F.; Galimberti, D.; Scarpini, E.; Mann, D.; Lendon, C.; Campion, D.; Amouyel, P.; Davies, P.; Foskett, J. K.; Campagne, F.; Marambaud, P. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell, 2008, 133(7), 1149-1161.
47. Moreno-Ortega, A. J.; Ruiz-Nuno, A.; Garcia, A. G.; Cano-Abad, M. F. Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1. Biochem. Biophys. Res. Commun., 2010, 391(1), 722-726.
48. Cano-Abad, M. F.; Villarroya, M.; Garcia, A. G.; Gabilan, N. H.; Lopez, M. G. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem., 2001, 276(43), 39695-39704.
49. Lorrio, S.; Sobrado, M.; Arias, E.; Roda, J. M.; Garcia, A. G.; Lopez, M. G. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther., 2007, 322(2), 591-599.
50. Summers, W. K.; Majovski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med., 1986, 315(20), 1241-1245.
51. Mori, Y.; Mikala, G.; Varadi, G.; Kobayashi, T.; Koch, S.; Wakamori, M.; Schwartz, A. Molecular pharmacology of voltagedependent calcium channels. Jpn. J. Pharmacol., 1996, 72(2), 83-109.
52. Walgren, J. L.; Mitchell, M. D.; Thompson, D. C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 2005, 35(4), 325-361.
53. Marco-Contelles, J.; Perez-Mayoral, E.; Samadi, A.; Carreiras Mdo, C.; Soriano, E. Recent advances in the Friedlander reaction. Chem. Rev., 2009, 109(6), 2652-2671.
54. Cheng, C. C.; Yan, S. J. The Friedlander Synthesis of Quinolines. In Org. React., 1982; Vol. 28, pp 37-201.
55. Martinez-Grau, A.; Marco, J. L. Friedlander reaction on 2-amino-3- cyano-4H-pyrans: Synthesis of derivatives of 4H-pyran[2,3-b] quinoline, new tacrine analogues. Bioorg. Med. Chem. Lett., 1997, 7(24), 3165-3170.
56. Martin, N.; MartinezGrau, A.; Seoane, C.; Marco, J. L.; Albert, A.; Cano, F. H. First asymmetric synthesis of 3-alkoxycarbonyl-2- amino-4-aryl-4H-naphtho[1,2-b]pyrans. J. Heterocyclic Chem., 1996, 33(1), 27-31.
57. Quintela, J. M.; Peinador, C.; Botana, L.; Estevez, M.; Riguera, R. Synthesis and antihistaminic activity of 2-guanadino-3- cyanopyridines and pyrido[2,3-d]-pyrimidines. Bioorg. Med. Chem., 1997, 5(8), 1543-1553.
58. Veronese, A. C.; Callegari, R.; Salah, S. A. A. Tin (Iv) chloridepromoted reactions of beta-dicarbonyl compounds with nitriles - synthesis of aminopyridines and aminoquinolines. Tetrahedron Lett., 1990, 31(24), 3485-3488.
59. Seijas, J. A.; Vazquez-Tato, M. P.; Martinez, M. M. Microwave enhanced synthesis of 4-aminoquinazolines. Tetrahedron Lett., 2000, 41(13), 2215-2217.
60. Shirai, K.; Fukunishi, K.; Yanagisawa, A.; Takahashi, H.; Matsuoka, M. New syntheses and spectral properties of pteridine-related heterocycles from 2,5-diamino-3,6-dicyanopyrazine. J. Heterocyclic Chem., 2000, 37(5), 1151-1156.
61. Marchalin, T.; Cvopova, K.; Pham-Huu, D. P.; Chudik, M.; Kozisek, J.; Svoboda, I.; Daich, A. Novel syntheses of densely functionalized indolizines, di- and tetrahydroindolizines from 2- formyl-1,4-dihydropyridine systems based on cascade process. Tetrahedron Lett., 2001, 42(33), 5663-5667.
62. de los Rios, C.; Marco, J. L.; Carreiras, M. D.; Chinchon, P. M.; Garcia, A. G.; Villarroya, M. Novel tacrine derivatives that block neuronal calcium channels. Bioorg. Med. Chem., 2002, 10(6), 2077-2088.
63. Marco, J. L.; de los Rios, C.; Garcia, A. G.; Villarroya, M.; Carreiras, M. C.; Martins, C.; Eleuterio, A.; Morreale, A.; Orozco, M.; Luque, F. J. Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors. Bioorg. Med. Chem., 2004, 12(9), 2199-2218.
64. Rappaport, F.; Fischl, J.; Pinto, N. An improved method for the estimation of cholinesterase activity in serum. Clin. Chim. Acta, 1959, 4(2), 227-230.
65. Marco, J. L.; de los Rios, C.; Carreiras, M. C.; Banos, J. E.; Badia, A.; Vivas, N. M. Synthesis and acetylcholinesterase/ butyrylcholinesterase inhibition activity of new tacrinelike analogues. Bioorg. Med. Chem., 2001, 9(3), 727-732.
66. Radic, Z.; Reiner, E.; Taylor, P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol. Pharmacol., 1991, 39(1), 98-104.
67. Albillos, A.; Garcia, A. G.; Olivera, B.; Gandia, L. Re-evaluation of the P/Q Ca2+ channel components of Ba2+ currents in bovine chromaffin cells superfused with solutions containing low and high Ba2+ concentrations. Pflug. Arch., 1996, 432(6), 1030-1038.
68. Coupland, R. E.; Hopwood, D. The mechanism of the differential staining reaction for adrenaline-and noreadrenaline-storing granules in tissues fixed in glutaraldehyde. J. Anat., 1966, 100(Pt 2), 227-243.
69. Garcia, A. G.; Garcia-De-Diego, A. M.; Gandia, L.; Borges, R.; Garcia-Sancho, J. Calcium signaling and exocytosis in adrenal chromaffin cells. Physiol. Rev., 2006, 86(4), 1093-1131.
70. Patterson, P. H. Control of cell fate in a vertebrate neurogenic lineage. Cell, 1990, 62(6), 1035-1038.
71. Villarroya, M.; Lopez, M. G.; Cano-Abad, M. F.; Garcia, A. G. Measurement of Ca2+ entry using 45Ca2+. Methods Mol. Biol., 2006, 312, 135-145.
72. Peng, Y.; Zhang, Q.; Snyder, G. L.; Zhu, H.; Yao, W.; Tomesch, J.; Papke, R. L.; O'Callaghan, J. P.; Welsh, W. J.; Wennogle, L. P. Discovery of novel alpha7 nicotinic receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20(16), 4825-4830.
73. Cannady, R.; Weir, R.; Wee, B.; Gotschlich, E.; Kolia, N.; Lau, E.; Brotherton, J.; Levin, E. D. Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function. Biochem. Pharmacol., 2009, 78(7), 788-794.
74. Arthur, D.; Levin, E. D. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology (Berl), 2002, 160(2), 140-145.
75. Shutske, G. M.; Kapples, K. J. Preparation of fused heterocyclic aminotetrahydroquinolinols and related compounds as memory enhancers US Patent, 1988, 4753950.
76. Desai, M. C. Tricyclic 4-aminopyridine derivatives for treatment of Alzheimer's disease, and their pharmaceutical compositions, preparation, and intermediates Eur. Patent, 1989, 311-303.
77. Chaki, H.; Yamabe, H.; Sugano, M.; Morita, S.; Bessho, T.; Tabata, R.; Saito, K. I.; Egawa, M.; Tobe, A.; Morinaka, Y. Design and syntheses of 4-acylaminopyridine derivatives - novel highaffinity choline uptake enhancers.2. Bioorg. Med. Chem. Lett., 1995, 5(14), 1495-1500.
78. Gewald, K. Heterocyclen Aus Ch-Aciden Nitrilen.9. Uber die reaktion von alpha-hydroxy-ketonen mit malodinitril. Chem. Ber.- Recueil., 1966, 99(3), 1002-&.
79. Feng, X.; Lancelot, J. C.; Prunier, H.; Rault, S. First synthesis of 4H-furo[3,2-f]pyrrolo[1,2-alpha][1,4]diazepines. J. Heterocyclic. Chem., 1996, 33(6), 2007-2011.
80. Marco, J. L.; De Los Rios, C.; Carreiras, M. C.; Banos, J. E.; Badia, A.; Vivas, N. M. Synthesis and acetylcholinesterase/ butyrylcholinesterase inhibition activity of 4-amino-2, 3-diaryl- 5, 6, 7, 8-tetrahydrofuro(and thieno)[2, 3-b]-quinolines, and 4- amino-5, 6, 7, 8, 9-pentahydro-2, 3-diphenylcyclohepta[e]furo(and thieno)-[2, 3-b]pyridines. Arch. Pharm. (Weinheim) 2002, 335(7), 347-353.
81. Taylor, E. C.; Berger, J. G. Heterocyclic Syntheses from OAminonitriles.24. a New Synthesis of 5-Substituted Pyrimidines. J. Org. Chem., 1967, 32(8), 2376-&.
82. Gewald, K.; Schinke, E.; Bottcher, H. 2-Amino-Thiophene Aus Methylenaktiven Nitrilen Carbonylverbindungen Und Schwefel. Chem. Ber.-Recueil., 1966, 99(1), 94.
83. Marco, J. L.; de los Ríos, C.; Carreiras, M. C.; Baños, J. E.; Badia, A.; Vivas, N. M.; Morreale, A.; Barrero, M.; Iriepa, I.; Gálvez, E. Síntesis, evaluación de la actividad como inhibidores de Acetilcolinesterasa/ Butirilcolinesterasa y análisis computacional de 4- amino-2,3-diaril-5,6,7,8-tetrahidrofuro (y tiofeno)[2,3-b]quinolinas, y 4-amino-5,6,7,8,9-pentahidro-2,3-difenilciclohepta[e]furo (y tiofeno) [2,3-b]piridinas como nuevos análogos de tacrina. XII Congress of Spanish Society of Therapeutic Chemistry, Seville, Spain 2001.
84. del Monte-Millan, M.; Garcia-Palomero, E.; Valenzuela, R.; Usan, P.; de Austria, C.; Munoz-Ruiz, P.; Rubio, L.; Dorronsoro, I.; Martinez, A.; Medina, M. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J. Mol. Neurosci., 2006, 30(1-2), 85-88.
85. Darvesh, S.; Hopkins, D. A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4(2), 131-138.
86. Orozco, C.; de Los Rios, C.; Arias, E.; Leon, R.; Garcia, A. G.; Marco, J. L.; Villarroya, M.; Lopez, M. G. ITH4012 (ethyl 5- amino-6,7,8,9-tetrahydro-2-methyl-4- phenylbenzol[1,8]naphthyridine-3-car boxylate), a novel acetylcholinesterase inhibitor with calcium promotor and neuroprotective properties. J. Pharmacol. Exp. Ther., 2004, 310(3), 987-994.
87. Wei, H.; Wei, W.; Bredesen, D. E.; Perry, D. C. Bcl-2 protects against apoptosis in neuronal cell line caused by thapsigargininduced depletion of intracellular calcium stores. J. Neurochem., 1998, 70(6), 2305-2314.
88. Maroto, R.; De la Fuente, M. T.; Artalejo, A. R.; Abad, F.; Lopez, M. G.; Garcia-Sancho, J.; Garcia, A. G. Effects of Ca2+ channel antagonists on chromaffin cell death and cytosolic Ca2+ oscillations induced by veratridine. Eur. J. Pharmacol., 1994, 270(4), 331-339.
89. C. de los Ríos, E. A., M.G. López, J.L. Marco, M. Villarroya, A.G. García "New Acetylcholinesterase inhibitors that modulate the cellular calcium: a possible neuroprotectant effect. 17th International Symposium on Medicinal Chemistry. Barcelona. Spain. Drugs Future, 2002, 27 (Suppl.A), 195; P204.
90. Pallaghy, P. K.; Norton, R. S. Refined solution structure of omegaconotoxin GVIA: implications for calcium channel binding. J. Pept. Res., 1999, 53(3), 343-351.
91. Albillos, A.; Garcia, A. G.; Gandia, L. omega-Agatoxin-IVAsensitive calcium channels in bovine chromaffin cells. FEBS Lett., 1993, 336(2), 259-262.
92. Schramm, M.; Thomas, G.; Towart, R.; Franckowiak, G. Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature, 1983, 303(5917), 535-537.
93. Priego, J.; Gonzalez-Morales, M. A.; Cillero, F. J.; Villarroya, M.; Sunkel, C.; de Casa-Juana, M. F.; Lopez, M. G.; Artalejo, C. R.; de Pascual, R.; Garcia, A. G. PCA 50941, a novel Ca2+ channel agonist. Eur. J. Pharmacol., 1993, 243(1), 25-34.
94. Collins, F.; Lile, J. D. The role of dihydropyridine-sensitive voltage- gated calcium channels in potassium-mediated neuronal survival. Brain Res., 1989, 502(1), 99-108.
95. Koike, T.; Martin, D. P.; Johnson, E. M., Jr. Role of Ca2+ channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor deprivation: evidence that levels of internal Ca2+ determine nerve growth factor dependence of sympathetic ganglion cells. Proc. Natl. Acad. Sci. USA, 1989, 86(16), 6421- 6425.
96. Chan, S. L.; Fu, W.; Zhang, P.; Cheng, A.; Lee, J.; Kokame, K.; Mattson, M. P. Herp stabilizes neuronal Ca2+ homeostasis and mitochondrial function during endoplasmic reticulum stress. J. Biol. Chem., 2004, 279(27), 28733-28743.
97. Thastrup, O.; Cullen, P. J.; Drobak, B. K.; Hanley, M. R.; Dawson, A. P. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc. Natl. Acad. Sci. USA, 1990, 87(7), 2466- 2470.
98. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. Charmm - a Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem., 1983, 4(2), 187-217.
99. Szabadkai, G.; Pitter, J. G.; Spat, A. Cytoplasmic Ca2+ at low submicromolar concentration stimulates mitochondrial metabolism in rat luteal cells. Pflug. Arch., 2001, 441(5), 678-685.
100. Sobrado, M.; Roda, J. M.; Lopez, M. G.; Egea, J.; Garcia, A. G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci. Lett., 2004, 365(2), 132-136.
101. Egea, J.; Rosa, A. O.; Sobrado, M.; Gandia, L.; Lopez, M. G.; Garcia, A. G. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience, 2007, 145(3), 866-872.
102. de los Rios, C.; Egea, J.; Marco-Contelles, J.; Leon, R.; Samadi, A.; Iriepa, I.; Moraleda, I.; Galvez, E.; Garcia, A. G.; Lopez, M. G.; Villarroya, M.; Romero, A. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J. Med. Chem., 2010, 53(14), 5129-5143.
103. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
104. Soriano, E.; Samadi, A.; Chioua, M.; de los Rios, C.; Marco- Contelles, J. Molecular modelling, synthesis and acetylcholinesterase inhibition of ethyl 5-amino-2-methyl-6,7,8,9- tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylat e. Bioorg. Med. Chem. Lett., 2010, 20(9), 2950-2953.
105. Ratia, M.; Gimenez-Llort, L.; Camps, P.; Munoz-Torrero, D.; Clos, M. V.; Badia, A. Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice. Pharmacol. Biochem. Behav., 2010, 95(4), 485-493.
106. Camps, P.; El Achab, R.; Morral, J.; Munoz-Torrero, D.; Badia, A.; Banos, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. New tacrine-huperzine A hybrids (huprines): highly potent tightbinding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J. Med. Chem., 2000, 43(24), 4657-4666.